201 related articles for article (PubMed ID: 38113870)
1. Atopy and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria.
Costa C; Esteves Caldeira L; Paulino M; Santos DF; Silva SL
Int Arch Allergy Immunol; 2024; 185(3):260-266. PubMed ID: 38113870
[TBL] [Abstract][Full Text] [Related]
2. Anti-TPO IgG/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria.
Brás R; Esteves Caldeira L; Bernardino A; Costa C
Int Arch Allergy Immunol; 2023; 184(9):866-869. PubMed ID: 37557083
[TBL] [Abstract][Full Text] [Related]
3. Higher House Dust Mite-Specific IgE Levels among Chronic Spontaneous Urticaria Patients May Implicate Higher Basophil Reactivity.
Liang G; Zhou J; Jiang L; Wang W; Wu Q; Gao C; Liu W; Li S; Feng S; Song Z
Int Arch Allergy Immunol; 2023; 184(11):1126-1134. PubMed ID: 37604140
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation.
Brás R; Costa C; Limão R; Caldeira LE; Paulino M; Pedro E
J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2392-2402. PubMed ID: 36720390
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria.
Zubiaga-Fernandez L; Testera-Montes A; Rondon C; Perez-Sanchez N; Gomez-Perez F; Vega-Chicote JM; Bartra J; Ferrer M; Eguiluz-Gracia I; Torres MJ
Clin Exp Allergy; 2024 Jun; 54(6):402-411. PubMed ID: 38343206
[TBL] [Abstract][Full Text] [Related]
6. Patients With Chronic Spontaneous Urticaria Who Have Wheals, Angioedema, or Both, Differ Demographically, Clinically, and in Response to Treatment-Results From CURE.
Buttgereit T; Vera C; Aulenbacher F; Church MK; Hawro T; Asero R; Bauer A; Bizjak M; Bouillet L; Dissemond J; Fomina D; Giménez-Arnau AM; Grattan C; Gregoriou S; Kulthanan K; Kasperska-Zajac A; Kocatürk E; Makris M; Kolkhir P; Weller K; Magerl M; Maurer M
J Allergy Clin Immunol Pract; 2023 Nov; 11(11):3515-3525.e4. PubMed ID: 37604426
[TBL] [Abstract][Full Text] [Related]
7. A Case-Control Study Comparing the General Characteristics of Patients with Symptomatic Dermographism and Chronic Spontaneous Urticaria: Is Atopy a Risk Factor for Symptomatic Dermographism?
Cakmak ME; Yegit OO; Öztop N
Int Arch Allergy Immunol; 2024; 185(3):247-252. PubMed ID: 38086338
[TBL] [Abstract][Full Text] [Related]
8. Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both.
Chen Y; Yu M; Huang X; Tu P; Shi P; Maurer M; Zhao Z
World Allergy Organ J; 2021 Jan; 14(1):100501. PubMed ID: 33510832
[TBL] [Abstract][Full Text] [Related]
9. Elevated baseline soluble FcεRI may be linked to early response to omalizumab treatment in chronic spontaneous urticaria.
Moñino-Romero S; Kolkhir P; Ohanyan T; Szépfalusi Z; Weller K; Metz M; Scheffel J; Maurer M; Altrichter S
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):167-174. PubMed ID: 37641982
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers of Autoimmune Chronic Spontaneous Urticaria.
Larenas-Linnemann D
Curr Allergy Asthma Rep; 2023 Dec; 23(12):655-664. PubMed ID: 38064133
[TBL] [Abstract][Full Text] [Related]
11. Remission of chronic urticaria in patients treated with omalizumab.
Cvenkel K; Bizjak M; Šelb J; Košnik M
Acta Dermatovenerol Alp Pannonica Adriat; 2024 Jun; 33(2):59-61. PubMed ID: 38741391
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory cytokine levels and changes during omalizumab treatment in chronic spontaneous urticaria.
Hoşgören-Tekin S; Eyüboğlu İP; Akkiprik M; Giménez-Arnau AM; Salman A
Arch Dermatol Res; 2024 May; 316(6):261. PubMed ID: 38795119
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review.
Gimenez-Arnau AM; Salman A; Podder I
Eur J Dermatol; 2024 Feb; 34(1):3-12. PubMed ID: 38557452
[TBL] [Abstract][Full Text] [Related]
14. Increased serum free IgE levels in patients with chronic spontaneous urticaria (CSU).
Jang JH; Yang EM; Lee Y; Ye YM; Moon J; Ryu MS; Park HS
World Allergy Organ J; 2022 Feb; 15(2):100629. PubMed ID: 35280503
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of drug therapies in antihistamine refractory chronic spontaneous urticaria: Real life data.
Unsel M
Asian Pac J Allergy Immunol; 2024 Jun; 42(2):138-146. PubMed ID: 33638629
[TBL] [Abstract][Full Text] [Related]
16. Depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticaria.
Can PK; Etikan P; Degirmentepe EN; Kocaturk E
Asian Pac J Allergy Immunol; 2024 Jun; 42(2):132-137. PubMed ID: 33638627
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-33, endothelin-1, and inflammatory parameters in chronic spontaneous urticaria.
Kulumbegov B; Chikovani T; Gotua M; Kikodze N; Magen E
Allergy Asthma Proc; 2023 Nov; 44(6):429-435. PubMed ID: 37919851
[No Abstract] [Full Text] [Related]
18. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
[No Abstract] [Full Text] [Related]
19. Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.
Jain V; Giménez-Arnau A; Hayama K; Reich A; Carr W; Tillinghast J; Dahale S; Lheritier K; Walsh P; Zharkov A; Hugot S; Haemmerle S
J Allergy Clin Immunol; 2024 Feb; 153(2):479-486.e4. PubMed ID: 37866460
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M; Ensina LF; Gimenez-Arnau AM; Sussman G; Hide M; Saini S; Grattan C; Fomina D; Rigopoulos D; Berard F; Canonica GW; Rockmann H; Irani C; Szepietowski JC; Leflein J; Bernstein JA; Peter JG; Kulthanan K; Godse K; Ardusso L; Ukhanova O; Staubach P; Sinclair R; Gogate S; Thomsen SF; Tanus T; Ye YM; Burciu A; Barve A; Modi D; Scosyrev E; Hua E; Letzelter K; Varanasi V; Patekar M; Severin T;
Lancet; 2024 Jan; 403(10422):147-159. PubMed ID: 38008109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
